D
David R. Spigel
Researcher at Sarah Cannon Research Institute
Publications - 526
Citations - 47699
David R. Spigel is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Lung cancer. The author has an hindex of 75, co-authored 526 publications receiving 38043 citations. Previous affiliations of David R. Spigel include Seattle Children's Research Institute & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more
TL;DR: Durvalumab therapy resulted in significantly longer overall survival than placebo, and no new safety signals were identified.
Journal ArticleDOI
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares,M. Dvorkin,Y. Chen,Niels Reinmuth,Katsuyuki Hotta,D. Trukhin,Galina Statsenko,Maximilian Hochmair,Mustafa Ozguroglu,J.H. Ji,Oleksandr Voitko,A. Poltoratskiy,Santiago Ponce,Francesco Verderame,Libor Havel,Igor Bondarenko,Andrzej Kazarnowicz,György Losonczy,Nikolay Conev,Jon Armstrong,N. Byrne,Norah J. Shire,Haiyi Jiang,Jonathan W. Goldman,Emilio Batagelj,Ignacio Casarini,Anea Viviana Pastor,Susana Noemi Sena,J. J. Zarba,Otto C. Burghuber,Sylvia Hartl,Bernd Lamprecht,Michael Studnicka,Luis Alberto Schlittler,Fabricio Augusto Martinelli de Oliveira,Aknar Calabrich,Gustavo Girotto,Peo Dos Reis,Carlos Fausto Nino Gorini,Peo Rafael Martins De Marchi,Clarissa Serodio da Rocha Baldotto,Claudia Sette,Mauro Zukin,Assen Dudov,Rumyana Ilieva,Krassimir Koynov,Rositsa Krasteva,Ivan Tonev,Spartak Valev,Violetka Venkova,Minghong Bi,Chengshui Chen,Yuan Chen,Zhendong Chen,Jian Fang,Jifeng Feng,Zhigang Han,Jie Hu,Yi Hu,Wei Li,Zongan Liang,Zhong Lin,Rui Ma,Shenglin Ma,Kejun Nan,Yongqian Shu,Kai Wang,Mengzhao Wang,Gang Wu,Nong Yang,Zhixiong Yang,Helong Zhang,Wei Zhang,Jun Zhao,Yanqiu Zhao,Caicun Zhou,Jianying Zhou,Xiangdong Zhou,Vitezslav Kolek,Leona Koubkova,Jaromir Roubec,Jana Skrickova,Milada Zemanova,Christos Chouaid,Werner Hilgers,Hervé Lena,Denis Moro-Sibilot,Gilles Robinet,Pierre-Jean Souquet,Jürgen Alt,Helge Bischoff,Christian Grohe,E. Laack,Susanne Lang,Jens Panse,Christian Schulz,Krisztina Bogos,Eszter Csánky,Anea Fülöp,Zsolt Horváth,Judit Kósa,Ibolya Laczó,Gábor Pajkos,Zsuzsanna Papai,Zsolt Pápai Székely,Veronika Sárosi,Attila Somfay,Éva Somogyiné Ezer,Anás Telekes,Jair Bar,Maya Gottfried,Norman Isaac Heching,Alona Zer Kuch,Roberta Bartolucci,Anna Cecilia Bettini,Angelo Delmonte,Marina Chiara Garassino,Mauro Minelli,F. Roila,Shinji Atagi,Koichi Azuma,Hisatsugu Goto,Koichi Goto,Yu Hara,Hidetoshi Hayashi,Toyoaki Hida,Kenya Kanazawa,Shintaro Kanda,Young Hak Kim,Shoichi Kuyama,Tadashi Maeda,Masahiro Morise,Yasuharu Nakahara,Makoto Nishio,Naoyuki Nogami,Isamu Okamoto,Haruhiro Saito,Masahiro Shinoda,Shigeki Umemura,Tatsuya Yoshida,Niels Claessens,Robin Cornelissen,Lizza Heniks,Jeroen Hiltermann,Egbert F. Smit,Agnes Staal van den Brekel,Dariusz M. Kowalski,Slawomir Mandziuk,Robert Mróz,Marek Z. Wojtukiewicz,Tudor Ciuleanu,Doina Ganea,Anei Ungureanu,Alexander Luft,Vladimir Moiseenko,Dina Sakaeva,Alexey Smolin,Alexander Vasilyev,Lyubov Vladimirova,Igor Anasina,Jozef Chovanec,Pavol Demo,Robert Godal,Peter Kasan,Marian Stresko,Michal Urda,Eun Kyung Cho,Joo Hang Kim,Sang-We Kim,Gyeong-Won Lee,Jongmin Lee,Ki Hyeong Lee,Kyung Hee Lee,Yun Gyoo Lee,Maria Amelia Insa Molla,Manuel Domine Gomez,Juan Ignacio Delgado Mingorance,Dolores Isla Casado,Marta Lopez Brea,Margarita Majem Tarruella,Teresa Morán Bueno,Alejano Navarro Mendivil,Luis Paz-Ares Rodríguez,Santiago Ponce Aix,Maria Rosario Garcia Campelo,Gee-Chen Chang,Yen-Hsun Chen,Chao-Hua Chiu,Te Chun Hsia,Kang-Yun Lee,Chien-Te Li,Chin-Chou Wang,Yu-Feng Wei,Shang-Yin Wu,Ahmet Alacacioglu,Irfan Cicin,Ahmet Demirkazik,Mustafa Erman,Tuncay Göksel,Hryhoriy Adamchuk,Oleksii Kolesnik,Anna Kryzhanivska,Yuriv Ostapenko,Serhii Shevnia,Yaroslav Shparyk,Grygorii Ursol,Nataliia Voitko,Ihor Vynnychenko,Sunil Babu,Anne Chiang,Winston Chua,Shaker R. Dakhil,Afshin Dowlati,Basir Haque,Rodney Jamil,Jeanna Knoble,Shailena Lakhanpal,Kailhong Mi,Petros Nikolinakos,Steven Francis Powell,Helen Ross,Eric Schaefer,Jeffrey Schneider,Joseph Spahr,David R. Spigel,Joseph Stilwill,Christopher Sumey,M. Williamson +227 more
TL;DR: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group and safety findings were consistent with the known safety profiles of all drugs received.
Journal ArticleDOI
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger,Leora Horn,Leena Gandhi,David R. Spigel,Scott J. Antonia,Naiyer A. Rizvi,John D. Powderly,Rebecca S. Heist,Richard D. Carvajal,David M. Jackman,Lecia V. Sequist,David Smith,Philip D. Leming,David P. Carbone,Mary Pinder-Schenck,Suzanne L. Topalian,F. Stephen Hodi,Jeffrey A. Sosman,Mario Sznol,David F. McDermott,Drew M. Pardoll,Vindira Sankar,Christoph Matthias Ahlers,Mark E. Salvati,Jon M. Wigginton,Matthew D. Hellmann,Georgia Kollia,Ashok Kumar Gupta,Julie R. Brahmer +28 more
TL;DR: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC, and overall survival, response durability, and long-term safety were reported.